HopeStage
Back to all studies
CompletedNCT02094898

Ketamine Study for Depression and Suicide Risk

About this title

Ketamine for Depression and Suicide Risk

Read the official source — NCT02094898
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

What did participation involve?

The study group receives ketamine as a study medication.

Listed locations
RochesterSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2014
Recruitment status
Completed
Enrollment listed in the registry
12
Sponsor
Mayo Clinic
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT02094898
Official title
Show the full official title

Acute and Maintenance Intravenous Ketamine for Treatment Resistant Major Depression With Suicidal Ideation/Attempt

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Rochester

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Mayo Clinic, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including ketamine.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies